Abstract: The disclosure relates to an omni-directional horizontally oriented deflecting tool for a coiled tubing, which includes an inner central pipe, an outer central pipe, a conical outer cylinder, a piston outer cylinder, an anchoring mechanism, a sealing mechanism, a reversing mechanism and a steering mechanism. The anchoring mechanism includes a cone, an O-shaped sealing ring I, a cone spring, a slip, a slip spring, a slip seat, a claw I and a pin shaft I, and the sealing mechanism includes a piston, an O-shaped sealing ring II, a claw II, a pin shaft II, an upper rubber cylinder seat, a rubber cylinder, a connecting cylinder, a lower rubber cylinder seat and a gasket.

Abstract: A method and a system for constructing a driving coordinate system for use in the field of smart transport. The method for constructing a driving coordinate system comprises: determining the road boundary line on one side of the road on which a current vehicle is situated as a reference line for constructing a driving coordinate system; in a vehicle coordinate system, determining the reference line point having the smallest distance between the reference line and the current vehicle position as an origin point OF of the driving coordinate system; on the basis of the origin point OF, determining the road guiding line direction as the XF axis of the driving coordinate system and determining the direction relative to the road guiding line direction according to the left-hand rule as the YF axis of the driving coordinate system; and, on the basis of the origin point OF, the XF axis, and the YF axis, forming a corresponding driving coordinate system.

Abstract: An application of a GABAA receptor allosteric enhancer in medicine.

Abstract: The disclosure provides a lyophilized preparation of prostaglandin E1 methyl ester for injection and production and use thereof. The lyophilized preparation comprises the following components by weight: 0.1-10 parts of prostaglandin E1 methyl ester, 500-4000 parts of an oil for injection, 500-2000 parts of an emulsifier, 0-10 parts of a co-emulsifier, 5000-50000 parts of a lyoprotectant, and 200-1500 parts of glycerin. The prostaglandin E1 methyl ester lyophilized agent of the disclosure has less blood vessel irritation, good drug stability, and superior drug activity and therapeutic effect than similar prostaglandin E1 products.

Abstract: The disclosure provides use of prostaglandin E1 methyl ester in the manufacture of a vasodilator. The prostaglandin E1 methyl ester has a structure represented by formula (I). the vasodilator is a drug for the treatment of microcirculation disorder, coronary heart disease, angina pectoris, heart failure, pulmonary heart disease, cerebral infarction, amniotic fluid embolism, or scleroderma.

Abstract: An application of a GABAA receptor allosteric enhancer in medicine.

Abstract: The present disclosure provides an allosteric enhancing compound of GABAA receptors or a prodrug thereof, a method for preparing the same, and use thereof. The compound is represented by formula (1), wherein R1 and R2 are each independently selected from isopropyl or n-propyl; and when R1 is n-propyl, R2 is not isopropyl.

Abstract: The present invention relates to use of biphenols in the preparation of a medicament for the prevention and treatment of ischemic stroke, specifically to use of 3,3?,5,5?-tetraisopropyl-4,4?-biphenol and salt, ester, or solvate thereof in the preparation of a medicament for the prevention and treatment of ischemic stroke injury.

Abstract: The present invention relates to a biphenyl derivative and use thereof, and the biphenyl derivative has a structure represented by the formula (I) as defined in the specification. The use refers the use of the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for the treatment and/or prevention of ischemic stroke.

Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.

Abstract: The present invention relates to use of biphenols in the preparation of a medicament for the prevention and treatment of ischemic stroke, specifically to use of 3,3?,5,5?-tetraisopropyl-4,4?-biphenol and salt, ester, or solvate thereof in the preparation of a medicament for the prevention and treatment of ischemic stroke injury.

Abstract: The present invention relates to a biphenyl derivative and use thereof, and the biphenyl derivative has a structure represented by the formula (I) as defined in the specification. The use refers the use of the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition comprising the biphenyl derivative or a pharmaceutically acceptable salt or solvate thereof in the preparation of a medicament for the treatment and/or prevention of ischemic stroke.

Abstract: Disclosed is a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2?,6,6?-tetraisopropyl-4,4?-biphenol, a solvent, and an antioxidant, among others.

Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.

Abstract: The present invention provides 3,3?,5,5?-tetraisopropyl-4,4?-diphenol crystal forms I, II and III, and preparation methods thereof. Crystal form I is superior to crystal form II in terms of stability under high temperature, high humidity, strong light and in water medium. The preparation methods for 3,3?,5,5?-tetraisopropyl-4,4?-diphenol crystal forms I, II and III provided in the invention are simple, easy to operate and suitable for industrial production.

Abstract: Disclosed is a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol soft capsule composed of a capsule shell and the contents in the capsule, wherein the contents in the capsule include 2,2?,6,6?-tetraisopropyl-4,4?-biphenol, a solvent, and an antioxidant, among others.

Abstract: This invention relates to a 2,2?,6,6?-tetraisopropyl-4,4?-biphenol lipid microsphere preparation having 2,2?,6,6?-tetraisopropyl-4,4?-biphenol as its active ingredient and formed into said lipid microsphere preparation with common medically used injection-grade oil, emulsifier, and injection-grade water.